SEOUL, July 30 - South Korea's Celltrion Inc on Thursday said British regulators had given it regulatory approval for a phase I clinical trial of its experimental COVID-19 treatment drug.
The company will enroll participants for a clinical study in the UK after approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), Celltrion said in a statement.
South Korean regulators on July 17 approved an early stage clinical trial for the drug, making it the country's first such antibody drug to be tested on humans.